部份中文FEROTRIN补血剂处方资料（仅供参考） FEROTRIN(hematinic concentrate with intrinsic factor) capsul 是用来治疗或预防铁的低血液水平（例如，贫血或怀孕期间）多种维生素产物。铁是一种重要的矿物质的身体需要产生红血细胞，并保持你身体健康。维生素C能改进铁从胃的吸收。维生素B12是对生长，细胞的生产，和神经功能的重要。内在因素是相同的，是在胃中自然制成的物质。它提高了维生素B12的吸收。 通用名称： 抗坏血酸，叶酸，氰钴胺素，富马酸亚铁，野猪胃和牛肝 剂型：胶囊 适应症和用法Ferotrin 该胶囊（壮阳药精矿内在因素）是一个多因素药品，有效的贫血的治疗，其中包括恶性贫血和巨幼红细胞等贫血症，也缺铁贫血。治疗量的造血因子被称为是重要存在于推荐日剂量。 FEROTRIN- ascorbic acid, folic acid, cyanocobalamin, ferrous fumarate, sus scrofa stomach and beef liver capsule  Boca Pharmacal, Inc. Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. DESCRIPTION EACH CAPSULE CONTAINS: Vitamin C (Ascorbic Acid)......................................75 mg. Folic Acid...............................................500 mcg. Vitamin B-12 (Cyanocobalamin).....................................15 mcg. Iron (Ferrous Fumarate)..........................................110 mg. Liver Stomach Concentrate (containing Intrinsic Factor)......................240 mg. Inactive Ingredients: D&C Red 28, Dicalcium Phospate,FD&C Blue 1,FD&C Green 3,FD&C Red 40, Gelatin, Magnesium Stearate, Pharmaceutical Glaze, and Titanium Dioxide. CLINICAL PHARMACOLOGY Vitamin B-12 with Intrinsic Factor - When secretion of intrinsic factor in gastric juice is inadequate or absent (e.g., in Addisonian pernicious anemia or after gastrectomy), vitamin B-12 in physiologic doses is absorbed poorly, if at all. Theresulting deficiency of vitamin B-12 leads to the clinical manifestations of pernicious anemia. Similar megaloblastic anemias may develop in fish tapeworm(Diphyllobothrium latum) infection or after a surgically created small-bowel blind loop; in these situations, treatment requires freeing the host of the parasites or bacteria that appear to compete for the available vitamin B-12. Strictvegetarianism and malabsorption syndromes may also lead to vitamin B-12 deficiency. In the latter case, parenteral therapy, or oral therapy with so-called massive doses of vitamin B-12, may be necessary for adequate treatment of the patient. Potency of intrinsic factor concentrates is determined physiologically, ie., by their use in patients with pernicious anemia. The liver-stomach concentrate withintrinsic factor and the vitamin B-12 contained in two Ferotrin Capsules provide 11/2 times the minimum amount of therapeutic agent, which, when given daily in an uncomplicated case of pernicious anemia, will produce a satisfactory reticulocyte response and relief of anemia and symptoms. Concentrates of intrinsic factor derived from hog gastric, pyloric and duodenal mucosa have been used successfully in patients who lack intrinsic factor. For example, Fouts et al maintained patients with pernicious anemia in clinicalremission with oral therapy (liver extracts or intrinsic factor concentrate with vitamin B-12) for as long as 29 years. After total gastrectomy, Ficarra found multifactor preparations taken orally to be "just as effective in maintaining blood levels as any medication that has to beadministered parenterally." His study was based on 24 patients who had survived for five years after total gastrectomy for cancer and who had been taking two Ferotrin Capsules daily. Folic Acid - Folic acid deficiency is the immediate cause of most, if not all, cases of nutritional megaloblastic anemia and of the megaloblastic anemias of pregnancy and infancy; usually, it is also at least partially responsible for the megaloblastic anemias of malabsorption syndromes, e.g., tropical and nontropical sprue. It is apparent that in vitamin B-12 deficiency (e.g., pernicious anemia), lack of this vitamin results in impaired utilization of folic acid. There are other evidences of the close folic acid-vitamin B-12 interrelationship: (1) B-12 influences the storage, absorption, and utilization of folic acid, and (2) as a deficiency of B-12 progresses, the requirement for folic acid increases. However, folic acid does not change the requirement for vitamin B-12. Iron - A very common anemia is that due to iron deficiency. In most cases, the response to iron salts is prompt, safe, and predictable. Within limits, the responseis quicker and more certain to large doses of iron than to small doses. EachFerotrin Capsule furnishes 110 mg. of elemental iron (as ferrous fumarate) to provide a maximum response. Ascorbic Acid - Vitamin C plays a role in anemia therapy. It augments theconversion of folic acid to its active form, folinic acid. In addition, ascorbic acidpromotes the reduction of ferric iron in food to the more readily absorbed ferrousform. Severe and prolonged vitamin C deficiency is associated with an anemia thatis usually hypochromic but occasionally megaloblastic in type. INDICATIONS AND USAGE This capsule (hematinic concentrate with intrinsic factor) is a multifactor preparation effective in the treatment of anemias that respond to oral hematinics, includingpernicious anemia and other megaloblastic anemias and also iron deficiencyanemia. Therapeutic quantities of hematopoietic factors that are known to beimportant are present in the recommended daily dose. CONTRAINDICATIONS Hemochromatosis and hemosiderosis are contraindications to iron therapy. WARNINGS Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six. Keep this product out of reach of children. In case of accidental overdose, call a doctor or Poison Control Center immediately. PRECAUTIONS General General: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Anemia is a manifestation that requires appropriate investigation to determine its cause or causes. Folic acid alone is unwarranted in the treatment of pure vitamin B12 deficiency states, such as pernicious anemia. Folic acid may obscure pernicious anemia in that the blood picture may revert to normal while neurological manifestations remain progressive. As with all preparations containing intrinsic factor, resistance may develop in some cases ofpernicious anemia to the potentiation of absorption of physiologic doses of vitamin B-12. Ifresistance occurs, parenteral therapy or oral therapy with so-called massive doses of vitaminB-12 may be necessary for adequate treatment of the patient. No single regimen fits allcases, and the status of the patient observed in follow-up is the final criterion for adequacy oftherapy. Periodic clinical and laboratory studies are considered essential and are recommended. Information for Patients Laboratory Tests Interactions Drug Interactions Drug/Laboratory Test Interactions Carcinogenesis, Mutagenesis, Impairment of Fertility Pregnancy Teratogenic Effects Pregnancy Category C: Animal reproduction studies have not been conducted with this product. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only if clearly needed. Nonteratogenic Effects Labor and Delivery Nursing Mothers It is not known whether this drug is excreted in human milk. Becausemany drugs are excreted in human milk, caution should be exercised when this product isadministered to a nursing woman. Pediatric Use Safety and effectiveness in children below the age of 10 have not been established. Geriatric Use Clinical studies on this product have not been performed in sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. ADVERSE REACTIONS Rarely, iron in therapeutic doses produces gastrointestinal reactions, such as diarrhea or constipation. Reducing the dose and administering it with meals will minimize these effects inthe iron-sensitive patient. In extremely rare instances, skin rash suggesting allergy has been noted following the oral administration of liver-stomach material. Allergic sensitization has been reported following both oral and parenteral administration of folic acid. DRUG ABUSE AND DEPENDENCE Controlled Substance Abuse Dependence OVERDOSAGE Symptoms: Those of iron intoxication, which may include pallor and cyanosis, vomiting, hematemesis, diarrhea, melena, shock, drowsiness, and coma. Treatment: For specific therapy, exchange transfusion and chelating agents. For general management, gastric and rectal lavage with sodium bicarbonate solution or milk, administration of intravenous fluids and electrolytes, and use of oxygen. DOSAGE AND ADMINISTRATION One capsule twice a day. (Two capsules daily produce a standard response in the average uncomplicated case of pernicious anemia.) HOW SUPPLIED Boxes of 60 capsules. STORAGE Store at controlled room temperature 20º-25ºC (68º-77ºF) [see USP Controlled Room Temperature].